At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SVRA Savara Inc
Closed 12-22 16:00:00 EST
6.47
+0.42
+6.94%
盘后6.36
-0.11-1.73%
19:58 EST
High6.48Low5.86Vol1.72M
Open5.98D1 Closing6.05Amplitude10.25%
Mkt Cap1.32BTradable Cap744.05MTotal Shares203.47M
T/O10.98MT/O Rate1.50%Tradable Shares115.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Savara Resubmits MOLBREEVI BLA to FDA and Requests Priority Review
Reuters  ·  12-22 21:31
Savara Resubmits MOLBREEVI BLA to FDA and Requests Priority Review
Savara Resubmits the Biologics License Application (Bla) to the U.S. Food and Drug Administration (FDA) for Molbreevi* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)
THOMSON REUTERS  ·  12-22 21:30
Savara Resubmits the Biologics License Application (Bla) to the U.S. Food and Drug Administration (FDA) for Molbreevi* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)
Savara Inc. : Wells Fargo Raises Target Price to $9 From $7
THOMSON REUTERS  ·  12-18
Savara Inc. : Wells Fargo Raises Target Price to $9 From $7
Savara Inc. Announces EPO Intention to Grant Patent for Liquid Formulation of MOLBREEVI
Reuters  ·  12-11
Savara Inc. Announces EPO Intention to Grant Patent for Liquid Formulation of MOLBREEVI
Savara Announces European Patent Office (Epo) Intends to Grant a Patent for the Liquid Formulation of Molbreevi*
THOMSON REUTERS  ·  12-11
Savara Announces European Patent Office (Epo) Intends to Grant a Patent for the Liquid Formulation of Molbreevi*
Savara Inc. Unveils New Therapies Targeting Rare Respiratory Diseases
Reuters  ·  12-02
Savara Inc. Unveils New Therapies Targeting Rare Respiratory Diseases
Savara Inc. and PARI Granted European Patent Covering MOLBREEVI and eFlow Nebulizer Combination
Reuters  ·  12-02
Savara Inc. and PARI Granted European Patent Covering MOLBREEVI and eFlow Nebulizer Combination
BUZZ-India's Mastek rises on report of promoters considering stake sale at premium
Reuters  ·  12-02
BUZZ-India's Mastek rises on report of promoters considering stake sale at premium
Master Tec Appoints Chong Peng Khang As CFO
Reuters  ·  11-21
Master Tec Appoints Chong Peng Khang As CFO
Master Tec Group Posts Qtrly Profit Attributable 8.6 Million RGT
Reuters  ·  11-21
Master Tec Group Posts Qtrly Profit Attributable 8.6 Million RGT
Savara Inc. to Participate in Piper Sandler Healthcare Conference
Reuters  ·  11-21
Savara Inc. to Participate in Piper Sandler Healthcare Conference
Savara Q3 Net Income USD -29.561 Million
Reuters  ·  11-20
Savara Q3 Net Income USD -29.561 Million
Savara Inc. Reports Q3 2025 Financial Results
TIPRANKS  ·  11-18
Savara Inc. Reports Q3 2025 Financial Results
Exploring High Growth Tech Stocks in the US Market
Simply Wall St.  ·  11-14
Exploring High Growth Tech Stocks in the US Market
Savara Is Maintained at Market Outperform by Citizens
Dow Jones  ·  11-13
Savara Is Maintained at Market Outperform by Citizens
Savara Q3 EPS $(0.14) Misses $(0.13) Estimate
Benzinga  ·  11-13
Savara Q3 EPS $(0.14) Misses $(0.13) Estimate
Savara Inc. Unveils Corporate Presentation on New Therapies for Rare Respiratory Diseases
Reuters  ·  11-13
Savara Inc. Unveils Corporate Presentation on New Therapies for Rare Respiratory Diseases
Savara Inc. posts Q3 net loss of $29.6 million
Reuters  ·  11-13
Savara Inc. posts Q3 net loss of $29.6 million
BRIEF-Savara Q3 Net Income USD -29.561 Million
Reuters  ·  11-13
BRIEF-Savara Q3 Net Income USD -29.561 Million
Savara Q3 EPS USD -0.14
THOMSON REUTERS  ·  11-13
Savara Q3 EPS USD -0.14

Introduction

Company Name.
Savara Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Austin, Texas.
Issue price:
--